anastrozole

Back to Drugs List

Associated Genetic Biomarkers

Associated Diseases

Overview

Generic Name(s):

anastrozole

Trade Name(s):

Arimidex

NCI Definition [1]:

A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure. As a third-generation aromatase inhibitor, anastrozole selectively binds to and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis. In estrogen-dependent breast cancers, ananstrozole may inhibit tumor growth. (NCI04)

Biomarker-Directed Therapies

Anastrozole can be used in the treatment of breast carcinoma. ER Expression, ER Positive, and PR Expression are the most frequent biomarker inclusion criteria for use of anastrozole [2].

Breast Carcinoma +

Disease is predicted to be sensitive to anastrozole: -

Biomarker Criteria:

Sample must match all of the following:

Hormone Receptor Positive

Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN)

Note: Indicated for HR-positive breast cancer, as adjuvant treatment, and for locally advanced or metastatic breast cancer as first-line treatment or after progression on tamoxifen.

Biomarker Criteria: Sample must match all of the following: Hormone Receptor Positive	Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN)
	Note: Indicated for HR-positive breast cancer, as adjuvant treatment, and for locally advanced or metastatic breast cancer as first-line treatment or after progression on tamoxifen.

Biomarker Criteria:

Sample must match all of the following:

Hormone Receptor Positive

Clinical Setting(s): Adjuvant (NICE, SMC)

Note: Please note that NICE guidance stipulates estrogen receptor (ER) expression as the criterion for primary adjuvant therapy with anastrozole, not progesterone receptor (PR).

Biomarker Criteria: Sample must match all of the following: Hormone Receptor Positive	Clinical Setting(s): Adjuvant (NICE, SMC)
	Note: Please note that NICE guidance stipulates estrogen receptor (ER) expression as the criterion for primary adjuvant therapy with anastrozole, not progesterone receptor (PR).

Biomarker Criteria:

Sample must match all of the following:

Hormone Receptor Positive

Clinical Setting(s): Adjuvant (NICE, SMC)

Biomarker Criteria:

Sample must match all of the following:

Hormone Receptor Positive

Clinical Setting(s): Adjuvant (NICE, SMC)

Disease is predicted to be resistant to anastrozole: -

Biomarker Criteria:

Sample must match one or more of the following:

ESR1 E380Q, ESR1 L536H, ESR1 L536P, ESR1 R555C, ESR1 V392I, ESR1 V533M, ESR1 D538G, ESR1 L536Q, ESR1 L536R, ESR1 P535H, ESR1 S463P, ESR1 V534E, ESR1 Y537C, ESR1 Y537N, ESR1 Y537S

Clinical Setting(s): Metastatic (MCG)

Biomarker Criteria:

Sample must match one or more of the following:

ESR1 E380Q, ESR1 L536H, ESR1 L536P, ESR1 R555C, ESR1 V392I, ESR1 V533M, ESR1 D538G, ESR1 L536Q, ESR1 L536R, ESR1 P535H, ESR1 S463P, ESR1 V534E, ESR1 Y537C, ESR1 Y537N, ESR1 Y537S

Clinical Setting(s): Metastatic (MCG)

Clinical Trials

View Clinical Trials for anastrozole

Anastrozole has been investigated in 33 clinical trials, of which 24 are open and 9 are closed. Of the trials investigating anastrozole, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 19 are phase 2 (12 open), 6 are phase 3 (6 open), and 1 is no phase specified (1 open).

ER Positive, ER Expression, and PR Expression are the most frequent biomarker inclusion criteria for anastrozole clinical trials.

Breast carcinoma, invasive breast carcinoma, and breast adenocarcinoma are the most common diseases being investigated in anastrozole clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Anastrozole

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Anastrozole

This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating anastrozole and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:

Arimidex, 120511-73-1, anastrozol, anastrozole, anastrozole [chemical/ingredient], 2,2'-[5-(1h-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]di(2-methylpropionitrile), 1,3-benzenediacetonitrile, alpha,alpha,alpha',alpha'-tetramethyl-5-(1h-1,2,4-triazol-1-ylmethyl)-, anastrazole, 719344, alpha,alpha,alpha',alpha'-tetramethyl-5-(1h-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile, zd-1033, astra brand of anastrozole, 2,2'-[5-(1h-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]di(2-methylpropionitrile), anastrozole, ici-d1033, anastrazole, anastrozole (substance), alpha,alpha,alpha', alpha'-tetramethyl-5-(1h-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile, anas, astrazeneca brand of anastrozole, zeneca brand of anastrozole, zeneca zd 1033, anastrozole (product), alpha,alpha,alpha', alpha'-tetramethyl-5-(1h-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile, ici d1033, 2,2'-(5-(1h-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile), zd1033

Drug Categories [2]:

Aromatase inhibitors

Drug Target(s) [2]:

CYP19A1

NCIT ID [1]:

C1607

SNOMED ID [1]:

F-61B21

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Drugs /

Back to Drugs List

Associated Genetic Biomarkers

Associated Diseases

Overview

Biomarker-Directed Therapies

Clinical Trials

Drug Details

References

About

Molecular Medicine

Content Types